drugset / Trial / NCT06925724
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.
Timeline
- Start
- 2025-04-04
- Primary completion
- 2027-04
- Completion
- 2027-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Ivonescimab | Monoclonal antibody | 3200 mg | Intravenous |